Lineage Cell Therapeutics, Inc.
LCTXNYSE
$1.16
↓ -0.9%Jul 17 close · end-of-day
Price
1Y↑ +13.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$303.0M
Enterprise Value
$249.6M
P/E
—
P/S
20.5
P/B
5.6
EV/EBITDA
—
PEG
—
FCF Yield
-7.5%
Dividend Yield
—
Revenue (TTM)
$14.8M
Net Income (TTM)
-$64.2M
Free Cash Flow (TTM)
-$22.6M
Gross Margin
—
Operating Margin
-255.1%
Net Margin
-434.4%
ROE
-119.2%
ROIC
-6030.1%
Debt / Equity
—
Net Cash
$53.4M
Return 1Y
+17.2%
Company profile
OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, are in clinical trials to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.
- CEO
- Brian M. Culley
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- California
- Website
- lineagecell.com
Management & directors
- Culley Brian MPresident and CEO
- Samuel George A. IiiGeneral Counsel and Secretary
Roles derived from SEC Form 4 filings.
Earnings
LCTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.7M↑ +14.8%
Diluted EPS-$0.03↑ +50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $4.3M | $14.7M | $8.9M | $9.5M | $14.6M |
| Gross profit | $1.4M | $2.9M | $14.0M | $8.3M | — | — |
| Operating income | -$26.4M | -$49.2M | -$22.5M | -$24.7M | -$21.5M | -$36.6M |
| Net income | -$20.6M | -$43.0M | -$26.3M | -$21.5M | -$18.6M | -$63.5M |
| Diluted EPS | — | — | -$0.15 | -$0.12 | -$0.09 | -$0.28 |
| Operating cash flow | -$19.8M | -$23.6M | $1.1M | -$28.6M | -$23.1M | -$18.9M |
| Free cash flow | -$19.8M | -$23.9M | $646,000.00 | -$29.2M | -$23.7M | -$19.4M |
| Gross margin | 78.9% | 67.2% | 95.0% | 92.5% | — | — |
| Operating margin | -1448.4% | -1133.6% | -153.2% | -276.5% | -226.1% | -251.6% |
| Net margin | -1130.8% | -991.0% | -178.7% | -240.2% | -195.9% | -436.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $3.8M | $2.9M | $1.5M | $2.8M | $3.7M | $6.6M | $1.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.9M | -$3.8M | -$5.1M | -$6.5M | -$19.8M | -$3.8M | -$6.5M | -$7.6M |
| Net income | -$5.8M | -$3.0M | -$3.3M | -$4.1M | -$30.5M | -$29.8M | $851,000.00 | -$4.8M |
| Diluted EPS | -$0.03 | -$0.02 | $0.00 | -$0.02 | -$0.13 | -$0.13 | $0.00 | -$0.03 |
| Operating cash flow | -$5.2M | -$5.8M | -$6.3M | -$4.9M | -$5.5M | -$3.6M | -$4.9M | -$8.1M |
| Free cash flow | -$5.2M | -$5.9M | -$6.7M | -$5.0M | -$5.6M | -$3.6M | -$5.3M | -$8.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -416.7% | -101.6% | -178.2% | -433.1% | -715.4% | -102.9% | -99.1% | -440.2% |
| Net margin | -409.1% | -80.3% | -114.1% | -275.6% | -1101.8% | -809.0% | 12.9% | -279.0% |
Company news
Jul 14, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-12 | Culley Brian M· President and CEO | Buy | 15,000 | $1.63 | $24,375.00 | filing |
| 2026-02-11 | Culley Brian M· President and CEO | Tax withholding | 12,869 | $1.80 | $23,164.20 | filing |
| 2026-02-11 | Samuel George A. III· General Counsel and Secretary | Tax withholding | 2,502 | $1.80 | $4,503.60 | filing |
| 2026-02-11 | Samuel George A. III· General Counsel and Secretary | Option exercise | 6,075 | — | — | filing |
| 2026-02-11 | Culley Brian M· President and CEO | Option exercise | 31,250 | — | — | filing |
| 2025-12-19 | Culley Brian M· President and CEO | Tax withholding | 334 | $1.68 | $561.12 | filing |
| 2025-12-19 | Samuel George A. III· General Counsel and Secretary | Tax withholding | 65 | $1.68 | $109.20 | filing |
| 2025-12-19 | Culley Brian M· President and CEO | Award | 8,925 | — | — | filing |
| 2025-12-19 | Samuel George A. III· General Counsel and Secretary | Award | 1,735 | — | — | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.